Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corcept Therapeutics Incorporated before investing.

In this article, we go over a few key elements for understanding Corcept Therapeutics Incorporated’s stock price such as:

• Corcept Therapeutics Incorporated’s current stock price and volume
• Why Corcept Therapeutics Incorporated’s stock price changed recently
• Upgrades and downgrades for CORT from analysts
• CORT’s stock price momentum as measured by its relative strength

About Corcept Therapeutics Incorporated (CORT)

Before we jump into Corcept Therapeutics Incorporated’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Want to learn more about Corcept Therapeutics Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated’s Stock Price as of Market Close

As of August 07, 2026, 4:00 PM, CST, Corcept Therapeutics Incorporated’s stock price was $110.770.

Corcept Therapeutics Incorporated is up 2.61% from its previous closing price of $107.950.

During the last market session, Corcept Therapeutics Incorporated’s stock traded between $108.075 and $110.790. Currently, there are approximately 105.38 million shares outstanding for Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated’s price-earnings (P/E) ratio is currently at 244.0, which is high compared to the Pharmaceuticals industry median of 20. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Corcept Therapeutics Incorporated Stock Price History

Corcept Therapeutics Incorporated’s (CORT) price is currently down 3.25% so far this month.

During the month of August, Corcept Therapeutics Incorporated’s stock price has reached a high of $115.000 and a low of $107.320.

Over the last year, Corcept Therapeutics Incorporated has hit prices as high as $122.210 and as low as $28.660. Year to date, Corcept Therapeutics Incorporated’s stock is up 218.3%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corcept Therapeutics Incorporated Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 07, 2026, there was 1 analyst who downgraded Corcept Therapeutics Incorporated’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Corcept Therapeutics Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Corcept Therapeutics Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Corcept Therapeutics Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corcept Therapeutics Incorporated (CORT) by visiting AAII Stock Evaluator.

Relative Price Strength of Corcept Therapeutics Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 07, 2026, Corcept Therapeutics Incorporated has a weighted four-quarter relative price strength of 35.30%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Corcept Therapeutics Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corcept Therapeutics Incorporated Stock Price: Bottom Line

As of August 7, 2026, Corcept Therapeutics Incorporated’s stock price is $110.770, which is up 2.61% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Corcept Therapeutics Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.